'Confirmed ccyr' presentation slideshows

397 views • 39 slides

ASCO 2010, Abstract # LBA6500

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-month Efficacy and Safety from the Phase 3 DASISION Study

530 views • 25 slides

Kantarjian H et al. Proc ASCO 2011;Abstract 6510.

Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION. Kantarjian H et al. Proc ASCO 2011;Abstract 6510. DASISION Study Design. Dasatinib 100 mg QD (n = 259). R. Follow-up. 5 yrs. Imatinib 400 mg QD (n = 260).

252 views • 8 slides

Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-Month Efficacy and Safety from the Phase III DASISION Study. Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

318 views • 7 slides